Uncategorized
EyeGate reports $13.3 million net loss in 2016
EyeGate Pharmaceuticals reported a $13.3 million net loss in 2016 compared with an $8.4 million net loss in 2015, according to a company press release.Research and development costs were $8.4 million compared with $2.7 million in 2015, an increase attributed mostly to clinical activity, including the EGP-437 and CMHA-S product pipelines.